What should I do if I become drug-resistant after taking Zanubrutinib?

Each patient's situation is unique. If a patient develops drug resistance after taking zanubrutinib, the doctor should be informed in time, and the doctor will adjust the drug resistance treatment strategy according to different drug resistance reactions. Drug resistance is generally confirmed through genetic testing or other related methods to confirm the specific mechanism of drug resistance, which will help further determine appropriate treatment strategies.

The maximum plasma concentration of zanubrutinib (Cmax) and the area under the plasma drug concentration curve (AUC) over time increased proportionally within the dose range of 40 mg to 320 mg (0.13-1 times the total recommended daily dose). Limited systemic accumulation of zanubrutinib was observed after repeated dosing. Different inhibitors may have different mechanisms of resistance and may be more effective in certain cases of resistance. Resistance to zanubrutinib may be improved through alternative therapies, i.e., consideration of other treatment options, such as ibrutinib or other BTK inhibitors. Combining zanubrutinib with other targeted therapeutics or chemotherapy drugs can improve the therapeutic effect by acting on different signaling pathways or using multiple mechanisms of action to combat drug resistance. Clinical trials may evaluate novel targeted therapeutics, immunotherapies, or other treatment strategies to provide new solutions for drug-resistant conditions.

The original drug of zanubrutinib has been launched in China and has been included in the medical insurance. The price of 80mg*64 capsules per box may be around 6,000 yuan. The original drug of zanubrutinib marketed overseas is relatively expensive. There are currently no generic drugs of zanubrutinib on the market.